Holen Sie sich die Stockscreener-App
10.61
1.58%
-0.17
Handel nachbörslich:
10.61
Schlusskurs vom Vortag:
$10.78
Offen:
$10.85
24-Stunden-Volumen:
721.01K
Relative Volume:
0.85
Marktkapitalisierung:
$684.53M
Einnahmen:
$262.60M
Nettoeinkommen (Verlust:
$-80.80M
KGV:
-8.7246
EPS:
-1.2161
Netto-Cashflow:
$-275.70M
1W Leistung:
+3.82%
1M Leistung:
-2.21%
6M Leistung:
+10.87%
1J Leistung:
+39.06%
1-Tages-Spanne:
$10.28
$11.00
1-Wochen-Bereich:
$9.73
$11.40
52-Wochen-Spanne:
$5.90
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
10.61 | 695.50M | 262.60M | -80.80M | -275.70M | -1.2161 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-10-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-09-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
What Arvinas says on May 12: Q1 results and corporate update - Stock Titan
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 - Caledonian Record
ARVN Maintained by Citigroup -- Price Target Raised to $24 - GuruFocus
Arvinas/Pfizer To Announce Veppanu Commercialization Partner In Weeks - Citeline News & Insights
Arvinas (NASDAQ:ARVN) Shares Gap DownShould You Sell? - MarketBeat
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy - Benzinga
Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations - BioSpace
Protein degraders gain speed as Arvinas scores landmark approval - Pharma Voice
FDA clears Pfizer, Arvinas’ novel breast cancer therapy despite mixed data - BioSpace
Hussman Strategic Advisors Inc. Buys New Shares in Arvinas, Inc. $ARVN - MarketBeat
Arvinas’ Veppanu, First Breast Cancer Drug of Its Kind Approved by FDA, Seeks Commercialization Partner - geneonline.com
How The Arvinas (ARVN) Story Is Shifting With Vepdeg And ARV-102 Milestones - Yahoo Finance
FDA approves Pfizer-Arvinas breast cancer pill Veppanu for advanced cases - Investing.com
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
FDA Approves Pfizer and Arvinas Breast Cancer Drug - Intellectia AI
US FDA approves Pfizer, Arvinas' breast cancer drug - Reuters
Truist Financial Maintains Arvinas(ARVN.US) With Hold Rating, Announces Target Price $10 - Moomoo
FDA Approves Vepdegestrant for Advanced Breast Cancer Treatment - GuruFocus
Arvinas (NASDAQ:ARVN) Shares Up 9.9%What's Next? - MarketBeat
BTIG reiterates Arvinas stock rating on breast cancer drug approval By Investing.com - Investing.com South Africa
BTIG reiterates Arvinas stock rating on breast cancer drug approval - Investing.com
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA - BioPharma Dive
FDA approves first PROTAC drug for ESR1-mutated breast cancer - Stock Titan
VEPPANU Receives FDA Approval, Pioneering PROTAC Therapy Era - Intellectia AI
Arvinas (ARVN) Secures Early Approval for Vepdeg in Breast Cance - GuruFocus
Arvinas shares gain as FDA approves breast cancer drug Veppanu - Investing.com
US FDA approves Pfizer, Arvinas’ breast cancer drug - WKZO
Arvinas Gains First FDA Approval for Breast Cancer Drug - TipRanks
Pfizer, Arvinas breast cancer drug approved (update) (PFE:NYSE) - Seeking Alpha
Arvinas shares gain as FDA approves breast cancer drug Veppanu By Investing.com - Investing.com Canada
FDA approves Arvinas’ vepdegestrant for breast cancer treatment By Investing.com - Investing.com Canada
Arvinas announces FDA approval of Veppanu for treatment of ESR1m, ER+/HER2- advanced breast cancer - marketscreener.com
FDA clears Arvinas (NASDAQ: ARVN) VEPPANU for advanced breast cancer - Stock Titan
FDA approves Arvinas’ vepdegestrant for breast cancer treatment - Investing.com UK
Arvinas and Pfizer Announce FDA Approval of VEPPANU™ as First-Ever PROTAC for Advanced Breast Cancer Treatment - Quiver Quantitative
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) - GlobeNewswire
Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach - MSN
(ARVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
[ARS] ARVINAS, INC. SEC Filing - Stock Titan
Arvinas (NASDAQ: ARVN) details 2026 virtual meeting, director and pay votes - Stock Titan
Arvinas (NASDAQ:ARVN) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Vanguard Portfolio Management owns 3.92M Arvinas shares (ARVN) - Stock Titan
Arvinas CEO John Houston to retire - MSN
Arvinas stock slides after eliminating trials, reducing workforce - MSN
Arvinas, Inc. (ARVN) reports Q4 loss, misses revenue estimates - MSN
Arvinas announces $100M share repurchase program - MSN
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
Arvinas (ARVN) moves 6.9% higher: Will this strength last? - MSN
Arvinas earns relative strength rating upgrade; hits key benchmark - MSN
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):